カテゴリー： 世界, 医療/バイオ, Grand View Research

世界のヘモグロビン異常症市場2023-2030：種類別（サラセミア、鎌状赤血球症、その他のヘモグロビン（Hb）変異体）、診断別、治療法別、地域別

【英語タイトル】Hemoglobinopathies Market Size, Share & Trends Analysis Report By Type (Thalassemia, Sickle Cell Disease, Other Hemoglobin (Hb) Variants), By Diagnosis, By Therapy, By Region, And Segment Forecasts, 2023 - 2030

Grand View Researchが出版した調査資料（GRV23NOV020）・商品コード：GRV23NOV020
・発行会社（調査会社）：Grand View Research
・発行日：2023年9月
・ページ数：150
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後3営業日）
・調査対象地域：グローバル
・産業分野：医療
◆販売価格オプション（消費税別）
Single UserUSD5,950 ⇒換算￥904,400見積依頼/購入/質問フォーム
Multi User/Five UserUSD6,950 ⇒換算￥1,056,400見積依頼/購入/質問フォーム
Global/corporate LicenseUSD8,950 ⇒換算￥1,360,400見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
❖ レポートの概要 ❖

ヘモグロビン異常症市場の成長と動向
Grand View Research, Inc.の最新レポートによると、ヘモグロビン異常症の世界市場規模は2030年までに207億米ドルに達し、2023年から2030年までの年平均成長率は12.6%で拡大すると予測されています。同市場は、鎌状赤血球症（SCD）やサラセミアなどの疾患の有病率の増加により、着実な成長を遂げています。推進要因としては、診断技術の進歩、意識の高まり、医療インフラの改善などが挙げられます。さらに、革新的な治療法の開発や政府の取り組みも市場拡大に寄与しています。

近年、鎌状赤血球症の診断技術は大きく進歩しています。顕著な傾向のひとつは、疾患に関連する特定の変異を特定するための分子遺伝学的検査、特にDNA解析の利用が増加していることです。このアプローチにより、正確で精度の高い診断が可能となり、医療従事者は個人の鎌状赤血球形質またはSCDの有無を判断することができます。さらに、技術の進歩により、ポイントオブケア検査装置が開発され、資源が限られた環境でも迅速なスクリーニングと診断が可能になりました。このような診断技術の進歩は、早期発見と早期介入を促進するだけでなく、遺伝カウンセリングや、鎌状赤血球症を引き継ぐリスクのある人の家族計画を容易にします。

SCDやサラセミアを含むヘモグロビン異常症に対する治療の進歩は、近年有望な傾向を示しています。遺伝子治療アプローチの開発と利用は、市場で広く普及している傾向の一つです。遺伝子治療は、罹患細胞に機能的遺伝子を導入することにより、これらの疾患の原因となる遺伝子変異を修正することを目的としています。いくつかの臨床試験の成功により、患者の疾患症状の大幅な改善と輸血依存度の低下が実証されています。さらに、CRISPR-Cas9のような遺伝子編集技術の出現は、患者自身の細胞内の欠陥遺伝子を正確に修正する大きな可能性を秘めています。この革新的なアプローチは、前臨床試験で有望な結果を示しており、近い将来、ヘモグロビン異常症に対する根治的な選択肢を提供するかもしれません。さらに、輸血プロトコール、鉄キレート療法、幹細胞移植技術の向上などの支持療法の進歩は、ヘモグロビン血症患者の予後改善に貢献し続けています。
ヘモグロビン血症患者の予後改善に貢献し続けています。

ヘモグロビン異常症を治療するための新規治療法の開発への投資や資金調達の増加は、予測期間中の市場成長をさらに押し上げるでしょう。例えば、2023年5月、米国上院議員は、増加する鎌状赤血球症患者の生活の質を向上させ、鎌状赤血球症を治療する医療スタッフを支援するサービスのための資金を提供する法案「鎌状赤血球症ケア拡大法」を提出しました。さらに、ブロンクス血液研究基金（BBRF）のような民間基金は、サラセミアやその他のヘモグロビン異常症の研究と管理のための基盤を提供しています。

治療費の高騰は市場に悪影響を及ぼす可能性があります。例えば、米国国立衛生研究所（National Institutes of Health）が支援する新しい調査によると、鎌状赤血球症を患う64歳以下のアメリカ人は、鎌状赤血球症を患っていない人に比べ、一生涯にかかる医療費の自己負担額が約44,000米ドル高くなります。さらに、保険会社は鎌状赤血球症患者1人につき平均170万米ドルを負担しています。

ヘモグロビン異常症市場レポートハイライト

- 2022年のヘモグロビン異常症市場において、鎌状赤血球病セグメントは58.6%の最大シェアを占め、予測期間中に最も速い速度で成長する見込みです。この背景には、鎌状赤血球症治療へのアクセス改善に焦点を当てたバイオ医薬品企業や非営利団体によるイニシアチブの高まりがあります。

- 鎌状赤血球症診断分野はヘモグロビン異常症市場を支配し、北米および欧州における高い診断率に起因して、2022年には50.5%のシェアを占めました。

- 治療分野別では、鎌状赤血球症分野が2022年に62.1%の最大売上シェアを獲得しました。鎌状赤血球症を治療するための新規治療法開発のための政府資金と相まった広範な研究が、同分野の成長に寄与する主な要因です。

- 北米は、ヘモグロビン異常症に対する認知度の向上、医療施設の改善、新製品の上市がこの地域の成長を増大させる主な要因であるため、2022年には37.7%の最大収益シェアを占めました。

- アジア太平洋地域は予測期間中に最も速い成長率を示すと推定されます。鎌状赤血球症やサラセミアに罹患する患者が多いことが、今後数年間の市場成長を促進すると予想されます。

- 市場の主要企業は、Sangamo Therapeutics社、bluebird bio社、Global Blood Therapeutics社、Pfizer社、Emmaus Life Sciences社、Prolong Pharmaceuticals社、Celgene社、Bioverativ社、Gamida Cell社、Novartis AG社です。

第1章 調査方法・範囲
第2章 エグゼクティブサマリー
第3章 市場変数・傾向・範囲
第4章 世界のヘモグロビン異常症市場：種類別ビジネス分析
第5章 世界のヘモグロビン異常症市場：診断別ビジネス分析
第6章 世界のヘモグロビン異常症市場：治療法別ビジネス分析
第7章 世界のヘモグロビン異常症市場：地域別ビジネス分析
第8章 競争状況
第9章 アナリストビュー

グローバル市場調査レポート販売サイトのwww.marketreport.jpです。

❖ レポートの目次 ❖

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.1.1. Segment Definitions
1.1.1.1. Type segment
1.1.1.2. Diagnosis segment
1.1.1.3. Therapy segment
1.2. Regional Scope
1.3. Estimates and Forecast Timeline
1.4. Objectives
1.4.1. Objective – 1
1.4.2. Objective – 2
1.4.3. Objective – 3
1.5. Research Methodology
1.6. Information Procurement
1.6.1. Purchased Database
1.6.2. GVR’s Internal Database
1.6.3. Secondary Sources
1.6.4. Primary research
1.7. Information or Data Analysis
1.7.1. Data Analysis Models
1.8. Market Formulation & Validation
1.9. Model Details
1.9.1. Commodity Flow Analysis
1.10. List of Secondary Sources
1.11. List of Abbreviations
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Type Snapshot
2.3. Diagnosis and Therapy Snapshot
2.4. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Increasing prevalence of hemoglobinopathies in under – developed countries
3.2.1.2. High unmet needs
3.2.1.3. Increasing R&D investments
3.2.1.4. Initiatives to improve disease awareness levels
3.2.2. Market Restraint Analysis
3.2.2.1. Lack of healthcare infrastructure
3.2.2.2. High cost of treatment
3.3. Industry Analysis Tools
3.3.1. Porter’s Five Forces Analysis
3.3.2. PESTEL Analysis
3.3.3. COVID – 19 Impact Analysis
Chapter 4. Type Business Analysis
4.1. Hemoglobinopathies Market: Type Movement Analysis
4.2. Thalassemia
4.2.1. Thalassemia Market, 2018 – 2030 (USD Million)
4.3. Sickle Cell Disease
4.3.1. Sickle Cell Disease Market, 2018 – 2030 (USD Million)
4.4. Hb Variants
4.4.1. Hb Variants Market, 2018 – 2030 (USD Million)
Chapter 5. Diagnosis Business Analysis
5.1. Hemoglobinopathies Market: Diagnosis Movement Analysis
5.2. Thalassemia
5.2.1. Thalassemia Market, 2018 – 2030 (USD Million)
5.3. Sickle Cell Disease
5.3.1. Sickle Cell Disease Market, 2018 – 2030 (USD Million)
5.4. Hb Variants
5.4.1. Hb Variants Market, 2018 – 2030 (USD Million)
Chapter 6. Therapy Business Analysis
6.1. Hemoglobinopathies Market: Therapy Movement Analysis
6.2. Thalassemia
6.2.1. Thalassemia Market, 2018 – 2030 (USD Million)
6.3. Sickle Cell Disease
6.3.1. Sickle Cell Disease Market, 2018 – 2030 (USD Million)
6.4. Other Hb Variants
6.4.1. Other Hb Variants Market, 2018 – 2030 (USD Million)
Chapter 7. Regional Business Analysis
7.1. Hemoglobinopathies Market Share By Region, 2022 & 2030
7.2. North America
7.2.1. SWOT Analysis
7.2.2. North America Hemoglobinopathies Market, 2018 – 2030 (USD Million)
7.2.3. U.S.
7.2.3.1. Key Country Dynamics
7.2.3.2. Target Disease Prevalence
7.2.3.3. Competitive Scenario
7.2.3.4. Regulatory Framework
7.2.3.5. U.S. Hemoglobinopathies Market, 2018 – 2030 (USD Million)
7.2.4. Canada
7.2.4.1. Key Country Dynamics
7.2.4.2. Target Disease Prevalence
7.2.4.3. Competitive Scenario
7.2.4.4. Regulatory Framework
7.2.4.5. Canada Hemoglobinopathies Market, 2018 – 2030 (USD Million)
7.3. Europe
7.3.1. Europe Hemoglobinopathies Market, 2018 – 2030 (USD Million)
7.3.2. UK
7.3.2.1. Key Country Dynamics
7.3.2.2. Target Disease Prevalence
7.3.2.3. Competitive Scenario
7.3.2.4. Regulatory Framework
7.3.2.5. UK Hemoglobinopathies Market, 2018 – 2030 (USD Million)
7.3.3. Germany
7.3.3.1. Key Country Dynamics
7.3.3.2. Target Disease Prevalence
7.3.3.3. Competitive Scenario
7.3.3.4. Regulatory Framework
7.3.3.5. Germany Hemoglobinopathies Market, 2018 – 2030 (USD Million)
7.3.4. France
7.3.4.1. Key Country Dynamics
7.3.4.2. Target Disease Prevalence
7.3.4.3. Competitive Scenario
7.3.4.4. Regulatory Framework
7.3.4.5. France Hemoglobinopathies Market, 2018 – 2030 (USD Million)
7.3.5. Italy
7.3.5.1. Key Country Dynamics
7.3.5.2. Target Disease Prevalence
7.3.5.3. Competitive Scenario
7.3.5.4. Regulatory Framework
7.3.5.5. Italy Hemoglobinopathies Market, 2018 – 2030 (USD Million)
7.3.6. Spain
7.3.6.1. Key Country Dynamics
7.3.6.2. Target Disease Prevalence
7.3.6.3. Competitive Scenario
7.3.6.4. Regulatory Framework
7.3.6.5. Spain Hemoglobinopathies Market, 2018 – 2030 (USD Million)
7.3.7. Denmark
7.3.7.1. Key Country Dynamics
7.3.7.2. Target Disease Prevalence
7.3.7.3. Competitive Scenario
7.3.7.4. Regulatory Framework
7.3.7.5. Denmark Hemoglobinopathies Market, 2018 – 2030 (USD Million)
7.3.8. Sweden
7.3.8.1. Key Country Dynamics
7.3.8.2. Target Disease Prevalence
7.3.8.3. Competitive Scenario
7.3.8.4. Regulatory Framework
7.3.8.5. Sweden Hemoglobinopathies Market, 2018 – 2030 (USD Million)
7.3.9. Norway
7.3.9.1. Key Country Dynamics
7.3.9.2. Target Disease Prevalence
7.3.9.3. Competitive Scenario
7.3.9.4. Regulatory Framework
7.3.9.5. Norway Hemoglobinopathies Market, 2018 – 2030 (USD Million)
7.3.10. Russia
7.3.10.1. Key Country Dynamics
7.3.10.2. Target Disease Prevalence
7.3.10.3. Competitive Scenario
7.3.10.4. Regulatory Framework
7.3.10.5. Russia Hemoglobinopathies Market, 2018 – 2030 (USD Million)
7.4. Asia Pacific
7.4.1. Asia Pacific Hemoglobinopathies Market, 2018 – 2030 (USD Million)
7.4.2. Japan
7.4.2.1. Key Country Dynamics
7.4.2.2. Target Disease Prevalence
7.4.2.3. Competitive Scenario
7.4.2.4. Regulatory Framework
7.4.2.5. Japan Hemoglobinopathies Market, 2018 – 2030 (USD Million)
7.4.3. China
7.4.3.1. Key Country Dynamics
7.4.3.2. Target Disease Prevalence
7.4.3.3. Competitive Scenario
7.4.3.4. Regulatory Framework
7.4.3.5. China Hemoglobinopathies Market, 2018 – 2030 (USD Million)
7.4.4. India
7.4.4.1. Key Country Dynamics
7.4.4.2. Target Disease Prevalence
7.4.4.3. Competitive Scenario
7.4.4.4. Regulatory Framework
7.4.4.5. India Hemoglobinopathies Market, 2018 – 2030 (USD Million)
7.4.5. Australia
7.4.5.1. Key Country Dynamics
7.4.5.2. Target Disease Prevalence
7.4.5.3. Competitive Scenario
7.4.5.4. Regulatory Framework
7.4.5.5. Australia Hemoglobinopathies Market, 2018 – 2030 (USD Million)
7.4.6. Thailand
7.4.6.1. Key Country Dynamics
7.4.6.2. Target Disease Prevalence
7.4.6.3. Competitive Scenario
7.4.6.4. Regulatory Framework
7.4.6.5. Thailand Hemoglobinopathies Market, 2018 – 2030 (USD Million)
7.4.7. South Korea
7.4.7.1. Key Country Dynamics
7.4.7.2. Target Disease Prevalence
7.4.7.3. Competitive Scenario
7.4.7.4. Regulatory Framework
7.4.7.5. South Korea Hemoglobinopathies Market, 2018 – 2030 (USD Million)
7.4.8. Singapore
7.4.8.1. Key Country Dynamics
7.4.8.2. Target Disease Prevalence
7.4.8.3. Competitive Scenario
7.4.8.4. Regulatory Framework
7.4.8.5. Singapore Hemoglobinopathies Market, 2018 – 2030 (USD Million)
7.5. Latin America
7.5.1. Latin America Hemoglobinopathies Market, 2018 – 2030 (USD Million)
7.5.2. Brazil
7.5.2.1. Key Country Dynamics
7.5.2.2. Target Disease Prevalence
7.5.2.3. Competitive Scenario
7.5.2.4. Regulatory Framework
7.5.2.5. Brazil Hemoglobinopathies Market, 2018 – 2030 (USD Million)
7.5.3. Mexico
7.5.3.1. Key Country Dynamics
7.5.3.2. Target Disease Prevalence
7.5.3.3. Competitive Scenario
7.5.3.4. Regulatory Framework
7.5.3.5. Mexico Hemoglobinopathies Market, 2018 – 2030 (USD Million)
7.5.4. Argentina
7.5.4.1. Key Country Dynamics
7.5.4.2. Target Disease Prevalence
7.5.4.3. Competitive Scenario
7.5.4.4. Regulatory Framework
7.5.4.5. Argentina Hemoglobinopathies Market, 2018 – 2030 (USD Million)
7.6. MEA
7.6.1. MEA Hemoglobinopathies Market, 2018 – 2030 (USD Million)
7.6.2. South Africa
7.6.2.1. Key Country Dynamics
7.6.2.2. Target Disease Prevalence
7.6.2.3. Competitive Scenario
7.6.2.4. Regulatory Framework
7.6.2.5. South Africa Hemoglobinopathies Market, 2018 – 2030 (USD Million)
7.6.3. Saudi Arabia
7.6.3.1. Key Country Dynamics
7.6.3.2. Target Disease Prevalence
7.6.3.3. Competitive Scenario
7.6.3.4. Regulatory Framework
7.6.3.5. Saudi Arabia Hemoglobinopathies Market, 2018 – 2030 (USD Million)
7.6.4. UAE
7.6.4.1. Key Country Dynamics
7.6.4.2. Target Disease Prevalence
7.6.4.3. Competitive Scenario
7.6.4.4. Regulatory Framework
7.6.4.5. UAE Hemoglobinopathies Market, 2018 – 2030 (USD Million)
7.6.5. Kuwait
7.6.5.1. Key Country Dynamics
7.6.5.2. Target Disease Prevalence
7.6.5.3. Competitive Scenario
7.6.5.4. Regulatory Framework
7.6.5.5. Kuwait Hemoglobinopathies Market, 2018 – 2030 (USD Million)
Chapter 8. Competitive Landscape
8.1. Participant Categorization
8.1.1. Sangamo Therapeutics
8.1.1.1. Overview
8.1.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.1.1.3. Product Benchmarking
8.1.1.4. Strategic Initiatives
8.1.2. Bluebird bio, Inc.
8.1.2.1. Overview
8.1.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.1.2.3. Product Benchmarking
8.1.2.4. Strategic Initiatives
8.1.3. Global Blood Therapeutics, Inc
8.1.3.1. Overview
8.1.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.1.3.3. Product Benchmarking
8.1.3.4. Strategic Initiatives
8.1.4. Pfizer, Inc.
8.1.4.1. Overview
8.1.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.1.4.3. Product Benchmarking
8.1.4.4. Strategic Initiatives
8.1.5. Emmaus Life Sciences, Inc.
8.1.5.1. Overview
8.1.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.1.5.3. Product Benchmarking
8.1.5.4. Strategic Initiatives
8.1.6. Prolong Pharmaceuticals, LLC
8.1.6.1. Overview
8.1.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.1.6.3. Product Benchmarking
8.1.6.4. Strategic Initiatives
8.1.7. Celgene Corporation (BMS)
8.1.7.1. Overview
8.1.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.1.7.3. Product Benchmarking
8.1.7.4. Strategic Initiatives
8.1.8. Bioverativ, Inc. (Sanofi)
8.1.8.1. Overview
8.1.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.1.8.3. Product Benchmarking
8.1.8.4. Strategic Initiatives
8.1.9. Gamida Cell
8.1.9.1. Overview
8.1.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.1.9.3. Product Benchmarking
8.1.9.4. Strategic Initiatives
8.1.10. Novartis AG
8.1.10.1. Overview
8.1.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.1.10.3. Product Benchmarking
8.1.10.4. Strategic Initiatives
8.2. Participant’s Overview
8.3. Financial Performance
8.4. Product Benchmarking
8.5. Company Market Share Analysis, 2022
8.6. Strategy Mapping
8.6.1. Expansion
8.6.2. Acquisition
8.6.3. Product/Service Launch
8.6.4. Others
Chapter 9. Analyst View

List of Tables

Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 Global hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
Table 4 Global hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
Table 5 Global hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
Table 6 Global hemoglobinopathies market, by region, 2018 - 2030 (USD Million)
Table 7 North America hemoglobinopathies market, by country, 2018 - 2030 (USD Million)
Table 8 North America hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
Table 9 North America hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
Table 10 North America hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
Table 11 U.S. hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
Table 12 U.S. hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
Table 13 U.S. hemoglobinopathies Market, by therapy, 2018 - 2030 (USD Million)
Table 14 Canada hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
Table 15 Canada hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
Table 16 Canada hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
Table 17 Europe hemoglobinopathies market, by country, 2018 - 2030 (USD Million)
Table 18 Europe hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
Table 19 Europe hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
Table 20 Europe hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
Table 21 UK hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
Table 22 UK hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
Table 23 UK hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
Table 24 Germany hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
Table 25 Germany hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
Table 26 Germany hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
Table 27 France hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
Table 28 France hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
Table 29 France hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
Table 30 Italy hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
Table 31 Italy hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
Table 32 Italy hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
Table 33 Spain hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
Table 34 Spain hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
Table 35 Spain hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
Table 36 Denmark hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
Table 37 Denmark hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
Table 38 Denmark hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
Table 39 Sweden hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
Table 40 Sweden hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
Table 41 Sweden hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
Table 42 Norway hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
Table 43 Norway hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
Table 44 Norway hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
Table 45 Asia Pacific hemoglobinopathies market, by country, 2018 - 2030 (USD Million)
Table 46 Asia Pacific hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
Table 47 Asia Pacific hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
Table 48 Asia Pacific hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
Table 49 Japan hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
Table 50 Japan hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
Table 51 Japan hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
Table 52 China hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
Table 53 China hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
Table 54 China hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
Table 55 India hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
Table 56 India hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
Table 57 India hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
Table 58 South Korea hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
Table 59 South Korea hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
Table 60 South Korea hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
Table 61 Australia hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
Table 62 Australia hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
Table 63 Australia hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
Table 64 Singapore hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
Table 65 Singapore hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
Table 66 Singapore hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
Table 67 Thailand hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
Table 68 Thailand hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
Table 69 Thailand hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
Table 70 Latin America hemoglobinopathies market, by country, 2018 - 2030 (USD Million)
Table 71 Latin America hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
Table 72 Latin America hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
Table 73 Latin America hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
Table 74 Brazil hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
Table 75 Brazil hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
Table 76 Brazil hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
Table 77 Mexico hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
Table 78 Mexico hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
Table 79 Mexico hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
Table 80 Argentina hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
Table 81 Argentina hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
Table 82 Argentina hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
Table 83 Middle East & Africa hemoglobinopathies market, by country, 2018 - 2030 (USD Million)
Table 84 Middle East & Africa hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
Table 85 Middle East & Africa hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
Table 86 Middle East & Africa hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
Table 87 South Africa hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
Table 88 South Africa hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
Table 89 South Africa hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
Table 90 UAE hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
Table 91 UAE hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
Table 92 UAE hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
Table 93 Saudi Arabia hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
Table 94 Saudi Arabia hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
Table 95 Saudi Arabia hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
Table 96 Kuwait hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
Table 97 Kuwait hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
Table 98 Kuwait hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
Table 99 Company Overview
Table 100 Financial Performance
Table 101 Product Benchmarking
Table 102 Strategic Initiatives

List of Figures

Fig. 1 Hemoglobinopathies market segmentation
Fig. 2 Market research process
Fig. 3 Information procurement
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value chain - based sizing & forecasting
Fig. 7 Market formulation & validation
Fig. 8 Hemoglobinopathies market segmentation
Fig. 9 Market snapshot, 2022
Fig. 10 Market trends & outlook
Fig. 11 Market driver relevance analysis (current & future impact)
Fig. 12 Market restraint relevance analysis (current & future impact)
Fig. 13 PESTEL analysis
Fig. 14 Porter’s five forces analysis
Fig. 15 Global Hemoglobinopathies market: Type movement analysis
Fig. 16 Global Hemoglobinopathies market, for thalassemia, 2018 - 2030 (USD Million)
Fig. 17 Global Hemoglobinopathies market, for sickle cell disease, 2018 - 2030 (USD Million)
Fig. 18 Global Hemoglobinopathies market, for Hb variants, 2018 - 2030 (USD Million)
Fig. 19 Global Hemoglobinopathies market: Diagnosis movement analysis
Fig. 20 Global Hemoglobinopathies market, for thalassemia, 2018 - 2030 (USD Million)
Fig. 21 Global Hemoglobinopathies market, for sickle cell disease, 2018 - 2030 (USD Million)
Fig. 22 Global Hemoglobinopathies market, for Hb variants, 2018 - 2030 (USD Million)
Fig. 23 Global Hemoglobinopathies market: Therapy movement analysis
Fig. 24 Global Hemoglobinopathies market, for thalassemia, 2018 - 2030 (USD Million)
Fig. 25 Global Hemoglobinopathies market, for sickle cell disease, 2018 - 2030 (USD Million)
Fig. 26 Global Hemoglobinopathies market, for other Hb variants, 2018 - 2030 (USD Million)
Fig. 27 Regional marketplace: Key takeaways
Fig. 28 Regional outlook, 2022 & 2030
Fig. 29 Global Hemoglobinopathies market: Region movement analysis
Fig. 30 North America Hemoglobinopathies market, 2018 - 2030 (USD Million)
Fig. 31 U.S. Hemoglobinopathies market, 2018 - 2030 (USD Million)
Fig. 32 Canada Hemoglobinopathies market, 2018 - 2030 (USD Million)
Fig. 33 Europe Hemoglobinopathies market, 2018 - 2030 (USD Million)
Fig. 34 Germany Hemoglobinopathies market, 2018 - 2030 (USD Million)
Fig. 35 UK Hemoglobinopathies market, 2018 - 2030 (USD Million)
Fig. 36 France Hemoglobinopathies market, 2018 - 2030 (USD Million)
Fig. 37 Italy Hemoglobinopathies market, 2018 - 2030 (USD Million)
Fig. 38 Spain Hemoglobinopathies market, 2018 - 2030 (USD Million)
Fig. 39 Denmark Hemoglobinopathies market, 2018 - 2030 (USD Million)
Fig. 40 Sweden Hemoglobinopathies market, 2018 - 2030 (USD Million)
Fig. 41 Norway Hemoglobinopathies market, 2018 - 2030 (USD Million)
Fig. 42 Asia Pacific Hemoglobinopathies market, 2018 - 2030 (USD Million)
Fig. 43 Japan Hemoglobinopathies market, 2018 - 2030 (USD Million)
Fig. 44 China Hemoglobinopathies market, 2018 - 2030 (USD Million)
Fig. 45 India Hemoglobinopathies market, 2018 - 2030 (USD Million)
Fig. 46 Australia Hemoglobinopathies market, 2018 - 2030 (USD Million)
Fig. 47 South Korea Hemoglobinopathies market, 2018 - 2030 (USD Million)
Fig. 48 Thailand Hemoglobinopathies market, 2018 - 2030 (USD Million)
Fig. 49 Singapore Hemoglobinopathies market, 2018 - 2030 (USD Million)
Fig. 50 Latin America Hemoglobinopathies market, 2018 - 2030 (USD Million)
Fig. 51 Brazil Hemoglobinopathies market, 2018 - 2030 (USD Million)
Fig. 52 Mexico Hemoglobinopathies market, 2018 - 2030 (USD Million)
Fig. 53 Argentina Hemoglobinopathies market, 2018 - 2030 (USD Million)
Fig. 54 Middle East and Africa Hemoglobinopathies market, 2018 - 2030 (USD Million)
Fig. 55 South Africa Hemoglobinopathies market, 2018 - 2030 (USD Million)
Fig. 56 Saudi Arabia Hemoglobinopathies market, 2018 - 2030 (USD Million)
Fig. 57 UAE Hemoglobinopathies market, 2018 - 2030 (USD Million)
Fig. 58 Kuwait Hemoglobinopathies market, 2018 - 2030 (USD Million)

★調査レポート[世界のヘモグロビン異常症市場2023-2030：種類別（サラセミア、鎌状赤血球症、その他のヘモグロビン（Hb）変異体）、診断別、治療法別、地域別] (コード：GRV23NOV020)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界のヘモグロビン異常症市場2023-2030：種類別（サラセミア、鎌状赤血球症、その他のヘモグロビン（Hb）変異体）、診断別、治療法別、地域別]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • ヘモグロビン異常症治療のグローバル市場：サラセミア、アルファサラセミア、ベータサラセミア、鎌状赤血球症、その他
  • 世界の血友病市場2023-2030：種類別（血友病A）、治療種類別（オンデマンド）、治療法別（遺伝子治療、モノクローナル抗体）、流通チャネル別、地域別
  • 世界のT細胞療法市場2023-2030：治療法別（CAR-T細胞療法、TIL療法）、疾患別（血液悪性腫瘍（リンパ腫））
  • 世界の更年期障害市場2024-2030：治療法別（栄養補助食品、OTC医薬品）、地域別（北米、ヨーロッパ、中南米）
  • 世界の末期腎臓病市場2023-2030：治療法別（移植、透析）、地域別（アジア太平洋、北アメリカ、中東・アフリカ、ヨーロッパ、中南米）
  • 世界の結核治療薬市場2023-2030：疾患種類別（活動性結核、潜在性結核）、治療法別、投与経路別、剤形別、流通チャネル別、地域別
  • 世界の爪白癬市場2023-2030：種類別（遠位爪甲下型爪白癬、表在性白色型爪白癬、近位爪甲下型爪白癬）、治療法別（経口、外用）、地域別
  • 世界の糖尿病性足潰瘍治療市場2024-2030：治療法別（生物学的製剤、治療機器）、潰瘍種類別（虚血性、神経障害性）、最終用途別（病院、ASC）、地域別
  • 世界のゴーシェ病治療薬市場2023-2030：種類別（1型、2型、3型、その他）、治療法別（酵素補充療法、基質補充療法、その他）、地域別

    • ◆H&Iグローバルリサーチのお客様（例）◆